updated 3/2/2011 7:16:29 AM ET 2011-03-02T12:16:29

DALLAS, March 2, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Novavax Inc. (Nasdaq:NVAX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/NVAX

Novavax Inc. (NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, using advanced proprietary virus-like particle (VLP) technology. The Company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. NVAX is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.

For only $19 a month, you can sign up for our real-time stock alert service. Click here to join now: http://www.pennystocklive.com/premium-membership/

In the report, the analyst notes:

"NVAX shares gained 13.85%, a day after the vaccine developer announced a government contract worth up to $179.1 million to develop pandemic and seasonal influenza vaccines using its vaccine technology. The U.S. Department of Health and Human Services (HHS) awarded the Company $97 million over the first three years, with options for an additional two years, for a total potential value of $179.1 million.

"During the contract's three-year base period, NVAX will continue to develop its novel, clinical-stage influenza vaccines to address the Office of Biomedical Advanced Research and Development Authority's commitment to pandemic preparedness."

To read the entire report visit: www.microstockprofit.com/lp/NVAX

See what investors are saying about NVAX at http://www.stockhideout.com

Get breaking news on NVAX at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.86%
$30K home equity loan FICO 5.20%
$75K home equity loan FICO 4.57%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.40%
Cash Back Cards 17.92%
17.92%
Rewards Cards 17.13%
17.12%
Source: Bankrate.com